Fig. 3

Photographs of a patient in the retreatment group before and after IVR treatment. a The anterior segment image of the right eye of an infant with aggressive posterior retinopathy of prematurity (APROP) before intravitreal ranibizumab (IVR) treatment showing iris neovascularizations around the pupil (white arrowhead). b A fundus photograph of the same eye before IVR. c Six weeks after the first IVR, the iris neovascularizations regressed completely. d Six weeks after the first IVR, the plus disease and ridge regressed. e The plus disease reoccurred, and vitreous retinal hemorrhage was observed after 12 weeks of the first IVR. The infant underwent a second IVR. f Four weeks after the second IVR, the plus disease regressed. g Thirteen months after the first IVR treatment. h Three years after the first IVR treatment